Galapagos NV ADR (GLPG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $28.91 (+5.01%), Market cap $1.86B, P/E ratio 3.19, 52-week low–high $25.07 ~ $37.62.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Be
Financial statements, price targets, institutional (13F) holdings and related news for Galapagos NV ADR are updated in real time on BlackAll Trade.
Galapagos NV ADR trades at $28.91 (+5.01%). Real-time quotes and charts are available on BlackAll Trade.
Galapagos NV ADR has a market cap of about $1.86B. Its P/E ratio is 3.19.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in ph